Aubrey Capital Management Ltd Takes $2.30 Million Position in HealthEquity, Inc. (NASDAQ:HQY)

Aubrey Capital Management Ltd bought a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,000 shares of the company's stock, valued at approximately $2,298,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Arcadia Investment Management Corp MI purchased a new stake in HealthEquity in the 4th quarter worth $26,000. Versant Capital Management Inc purchased a new stake in HealthEquity in the 1st quarter worth $28,000. Transce3nd LLC bought a new position in shares of HealthEquity during the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC boosted its holdings in shares of HealthEquity by 34.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock valued at $37,000 after purchasing an additional 98 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in shares of HealthEquity during the 4th quarter valued at about $39,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at HealthEquity

In related news, EVP Elimelech Rosner sold 58,000 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the completion of the transaction, the executive vice president now owns 75,689 shares in the company, valued at $8,519,553.84. This represents a 43.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jon Kessler sold 134,183 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.08, for a total transaction of $15,039,230.64. Following the completion of the sale, the director now owns 253,510 shares of the company's stock, valued at approximately $28,413,400.80. The trade was a 34.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold 304,581 shares of company stock worth $33,664,018 over the last three months. Company insiders own 1.50% of the company's stock.

HealthEquity Stock Down 3.5%

HQY stock traded down $3.68 during trading on Monday, hitting $101.08. 1,490,013 shares of the company's stock traded hands, compared to its average volume of 839,527. The firm has a market capitalization of $8.74 billion, a P/E ratio of 92.73, a PEG ratio of 1.60 and a beta of 0.49. The business has a fifty day simple moving average of $94.45 and a two-hundred day simple moving average of $97.82. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 1 year low of $65.01 and a 1 year high of $116.65.

HealthEquity (NASDAQ:HQY - Get Free Report) last issued its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.16. The company had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period last year, the company posted $0.80 earnings per share. Sell-side analysts anticipate that HealthEquity, Inc. will post 2.32 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on HQY shares. Bank of America increased their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Barrington Research increased their price target on shares of HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a report on Thursday, June 5th. The Goldman Sachs Group increased their price target on shares of HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a report on Wednesday, June 4th. JMP Securities increased their price target on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a report on Wednesday, June 4th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $118.09.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.